-

VIA Transportation, Inc. Stock Drop: Harmed Investors Should Contact Robbins LLP for Information About Leading the Class Action Against VIA

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Via Transportation, Inc. (NYSE: VIA) in connection with the Company's September 15, 2025 initial public statement ("IPO"). Via Transportation, Inc. provides a platform that transforms global transportation systems into digital networks in the United States, Germany, and internationally.

VIA Transportation, Inc. Stock Drop: Harmed Investors Should Contact Robbins LLP for Information About Leading the Class Action Against VIA

Share

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

What are the allegations?

Shareholders allege that Via Transportation, Inc. misled investors regarding customer growth, revenue generation, and expansion opportunities. According to the complaint, Via Transportation, Inc.'s Registration Statement and Prospectus, filed with the SEC on August 15, 2025 and September 15, 2025, respectively, including all amendments thereto (collectively, the "Offering Documents"), contained materially false and misleading statements and omissions of material facts required to be disclosed under federal securities laws.

Plaintiff alleges that Via's September 15, 2025 IPO Offering Documents portrayed the Company as experiencing significant and durable revenue growth, highlighted the success of its "land and expand" strategy, and emphasized the importance of its German operations, while failing to disclose that the Company's growth was already facing obstacles. Specifically, Plaintiff alleges that Via was adding customers faster than those customers were generating revenue, resulting in a decline in Annual Run-Rate Revenue ("ARR") per customer for the first time in eight quarters, and that regulatory conditions in Germany were limiting the Company's ability to expand beyond its microtransit offerings and sell its broader platform. The truth began to emerge on November 13, 2025, when Via disclosed that ARR per customer had declined for the first time in eight quarters, causing the stock price to fall nearly 13% to close at $43.14 per share. Then, on February 27, 2026, the Company disclosed that it was facing headwinds in Germany and that regulatory challenges were delaying broader platform adoption, causing the stock price to fall nearly 8% to close at $17.18 per share. Finally, on May 12, 2026, Via disclosed continuing funding and regulatory pressures in Germany that were limiting growth, causing the stock price to fall more than 17% to close at $14.12 per share, nearly 70% below the $46 IPO price.

What can shareholders do now? You may be eligible to participate in the class action against Via Transportation, Inc. Shareholders who wish to serve as lead plaintiff for the class must submit their papers to the court by August 10, 2026. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.

To be notified if a class action against Via Transportation, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:VIA

Release Versions
$Cashtags

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Erasca, Inc. Class Action Reminder - Robbins LLP Encourages ERAS Stockholders to Contact the Firm for Information About Their Rights  

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Erasca, Inc. (NASDAQ: ERAS) securities between January 14, 2025 and April 26, 2026. Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call...

ADMA Biologics, Inc. Stock Drop: Robbins LLP Urges Investors to Contact the Firm for Information About the Class Action Against ADMA Biologics, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ADMA Biologics, Inc. (NASDAQ: ADMA) securities between August 9, 2024 and March 25, 2026. ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. For more information...

Investor Notice: Robbins LLP Informs Investors of the Regeneron Pharmaceuticals, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Regeneron Therapeutics, Inc. (NASDAQ: REGN) from August 1, 2025 to May 15, 2026. Regeneron is a pharmaceutical company that discovers, invents, develops, manufactures, tests, and commercializes medicines to treat various disorders worldwide.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The...
Back to Newsroom